Stan Crooke on Personalized Medicine — A Nautilus Fireside Chat

​Drug development favors scale, leaving patients with rare genetic diseases that affect only a handful of people worldwide with few or no options. Stanley Crooke has spent his career challenging that model.

​After leading work at major pharmaceutical firms and founding Ionis Pharmaceuticals, where he helped pioneer antisense technology, Crooke turned to a more radical approach: developing treatments for one patient at a time. Through his nonprofit, n-Lorem, he and his team create individualized therapies for patients with no other prospects, using an “N-of-1” model of drug development.

​In this conversation with journalist Brady Huggett, Crooke discusses what it will take to make truly personalized medicine a reality.

Guest: Stan Crooke
Dr. Stanley Crooke is founder, chairman, and CEO of n-Lorem, a nonprofit focused on providing treatments for those with nano-rare diseases (1 to 30 patients worldwide). He previously worked at Bristol-Myers, where he brought numerous anticancer drugs to market. He then led worldwide R&D at SmithKline Beckman (now GSK). He also founded Ionis Pharmaceuticals, where he helped develop a new platform for drug discovery, antisense technology, and the creation of one of the most advanced development pipelines in the biotechnology industry.

Host: Brady Huggett
Brady Huggett’s profile of Stan Crooke, “For Every Patient Their Own Drug,” can be found in the upcoming issue of Nautilus magazine. He currently serves as the features editor at The Transmitter and previously worked as an editor at Nature Biotechnology.

Read the story that inspired this event → https://nautil.us/for-every-patient-their-own-drug-1280433